Acrivon Therapeutics (ACRV) Competitors $1.36 +0.03 (+2.26%) Closing price 04:00 PM EasternExtended Trading$1.36 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRV vs. LFVN, CYBN, ACTU, NKTX, NVCT, BIOA, GLSI, CRDF, DERM, and CLLSShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Lifevantage (LFVN), Cybin (CYBN), Actuate Therapeutics (ACTU), Nkarta (NKTX), Nuvectis Pharma (NVCT), BioAge Labs (BIOA), Greenwich LifeSciences (GLSI), Cardiff Oncology (CRDF), Journey Medical (DERM), and Cellectis (CLLS). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. Its Competitors Lifevantage Cybin Actuate Therapeutics Nkarta Nuvectis Pharma BioAge Labs Greenwich LifeSciences Cardiff Oncology Journey Medical Cellectis Acrivon Therapeutics (NASDAQ:ACRV) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation. Which has more volatility and risk, ACRV or LFVN? Acrivon Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Lifevantage has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Which has higher valuation and earnings, ACRV or LFVN? Lifevantage has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcrivon TherapeuticsN/AN/A-$80.56M-$2.25-0.60Lifevantage$200.16M0.84$2.94M$0.6919.43 Does the media favor ACRV or LFVN? In the previous week, Lifevantage had 3 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 4 mentions for Lifevantage and 1 mentions for Acrivon Therapeutics. Lifevantage's average media sentiment score of 0.54 beat Acrivon Therapeutics' score of -0.04 indicating that Lifevantage is being referred to more favorably in the news media. Company Overall Sentiment Acrivon Therapeutics Neutral Lifevantage Positive Do analysts rate ACRV or LFVN? Acrivon Therapeutics currently has a consensus price target of $17.57, indicating a potential upside of 1,192.02%. Lifevantage has a consensus price target of $30.50, indicating a potential upside of 127.44%. Given Acrivon Therapeutics' higher possible upside, equities research analysts plainly believe Acrivon Therapeutics is more favorable than Lifevantage.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Lifevantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in ACRV or LFVN? 71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 35.3% of Lifevantage shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 20.7% of Lifevantage shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is ACRV or LFVN more profitable? Lifevantage has a net margin of 4.12% compared to Acrivon Therapeutics' net margin of 0.00%. Lifevantage's return on equity of 34.67% beat Acrivon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Acrivon TherapeuticsN/A -50.78% -46.08% Lifevantage 4.12%34.67%15.24% SummaryLifevantage beats Acrivon Therapeutics on 10 of the 15 factors compared between the two stocks. Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.78M$2.48B$5.74B$9.78BDividend YieldN/A1.67%4.40%4.04%P/E Ratio-0.6022.5330.8326.39Price / SalesN/A506.55382.9086.63Price / CashN/A178.3537.7259.11Price / Book0.306.2910.106.62Net Income-$80.56M$32.94M$3.26B$265.42M7 Day Performance4.62%2.27%3.90%3.58%1 Month Performance-4.90%1.06%3.73%0.46%1 Year Performance-85.19%5.65%37.68%19.41% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics2.6353 of 5 stars$1.36+2.3%$17.57+1,192.0%-85.9%$42.78MN/A-0.6058LFVNLifevantage4.025 of 5 stars$13.69+1.5%$30.50+122.8%+46.3%$169.81M$222.35M19.84260News CoveragePositive NewsCYBNCybin2.362 of 5 stars$6.92-2.0%$85.00+1,128.3%N/A$166.55MN/A-1.5850News CoverageACTUActuate TherapeuticsN/A$8.25+1.6%$20.50+148.5%+2.9%$166.22MN/A0.0010News CoverageAnalyst ForecastNKTXNkarta1.8913 of 5 stars$2.35+0.9%$13.60+478.7%-61.0%$165.49MN/A-1.59140NVCTNuvectis Pharma3.5089 of 5 stars$6.45+0.3%$15.33+137.7%-1.3%$163.69MN/A-5.518BIOABioAge LabsN/A$4.52-0.7%N/AN/A$163.12M$3.86M0.00N/AGLSIGreenwich LifeSciences1.7762 of 5 stars$12.01-1.3%$39.00+224.7%-18.4%$162.69MN/A-8.833CRDFCardiff Oncology2.4391 of 5 stars$2.43-0.4%$10.10+315.6%-7.9%$162.32M$680K-2.7920News CoveragePositive NewsDERMJourney Medical1.6875 of 5 stars$7.00+0.7%$10.83+54.8%+52.7%$161.91M$56.13M-18.4290Trending NewsAnalyst ForecastAnalyst RevisionCLLSCellectis3.4821 of 5 stars$2.90+1.8%$4.00+37.9%+8.8%$158.41M$56.30M-3.54290Positive NewsGap Up Related Companies and Tools Related Companies Lifevantage Competitors Cybin Competitors Actuate Therapeutics Competitors Nkarta Competitors Nuvectis Pharma Competitors BioAge Labs Competitors Greenwich LifeSciences Competitors Cardiff Oncology Competitors Journey Medical Competitors Cellectis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRV) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access